These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 1802902)

  • 21. Predicting progression to AIDS: combined usefulness of CD4 lymphocyte counts and p24 antigenemia.
    MacDonell KB; Chmiel JS; Poggensee L; Wu S; Phair JP
    Am J Med; 1990 Dec; 89(6):706-12. PubMed ID: 1979205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Acquired trichomegaly and hypertrichosis].
    Aerts L; Lauwers N; Smets RM
    J Fr Ophtalmol; 2014 Apr; 37(4):339-41. PubMed ID: 24576565
    [No Abstract]   [Full Text] [Related]  

  • 23. Detection of infectious immune complexes in human immunodeficiency virus type 1 (HIV-1) infections: correlation with plasma viremia and CD4 cell counts.
    Fiscus SA; Wallmark EB; Folds JD; Fryer J; van der Horst CM
    J Infect Dis; 1991 Oct; 164(4):765-9. PubMed ID: 1680137
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Essential trichomegaly: case report.
    Rossetto JD; Nascimento H; Muccioli C; Belfort R
    Arq Bras Oftalmol; 2013; 76(1):50-1. PubMed ID: 23812530
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Acquired hypertrichosis of the eyelashes in AIDS].
    Janier M; Oksenhendler E; Civatte J
    Ann Dermatol Venereol; 1989; 116(8):559-61. PubMed ID: 2596800
    [No Abstract]   [Full Text] [Related]  

  • 26. [Acquired hypertrichosis of eyelashes in AIDS].
    Poizot-Martin I; Lafeuillade A; Gourgeonnet A; Dhiver C; Gamby T; Gastaut JA
    Ann Dermatol Venereol; 1992; 119(2):143-4. PubMed ID: 1605514
    [No Abstract]   [Full Text] [Related]  

  • 27. Serum p24 antigen level as an intermediate end point in clinical trials of zidovudine in people infected with human immunodeficiency virus type 1. Aids Clinical Trials Group Virology Laboratories.
    DeGruttola V; Beckett LA; Coombs RW; Arduino JM; Balfour HH; Rasheed S; Hollinger FB; Fischl MA; Volberding P
    J Infect Dis; 1994 Apr; 169(4):713-21. PubMed ID: 8133085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heat-denatured human immunodeficiency virus type 1 protein 24 antigen: prognostic value in adults with early-stage disease.
    Sterling TR; Hoover DR; Astemborski J; Vlahov D; Bartlett JG; Schupbach J
    J Infect Dis; 2002 Oct; 186(8):1181-5. PubMed ID: 12355373
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acquired eyelash trichomegaly and generalized hypertrichosis associated with breast anomaly.
    Aghaei S; Dastgheib L
    Dermatol Online J; 2006 Feb; 12(2):19. PubMed ID: 16638412
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intestinal mucosal inflammation associated with human immunodeficiency virus infection.
    Kotler DP; Reka S; Clayton F
    Dig Dis Sci; 1993 Jun; 38(6):1119-27. PubMed ID: 8508707
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Diagnostic reference. Human immunodeficiency virus].
    Porstmann T
    Wien Med Wochenschr; 1992; 142(17):396-8. PubMed ID: 1362310
    [No Abstract]   [Full Text] [Related]  

  • 32. p24 antibody production in p24 antibody-negative HIV-infected subjects.
    Stickler MC; Sharpe S; Zolla-Pazner S
    Viral Immunol; 1992; 5(2):123-32. PubMed ID: 1616583
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Trichomegaly: an unusual manifestation of acquired immunodeficiency syndrome?].
    Aguado JM; Echevarría S
    Med Clin (Barc); 1989 Dec; 93(18):715-6. PubMed ID: 2607827
    [No Abstract]   [Full Text] [Related]  

  • 34. Plasma immunotherapy in a child with acquired immunodeficiency syndrome.
    Wong VK; Gillette SG; Roth MJ; Miles S; Stiehm ER
    Pediatr Infect Dis J; 1993 Nov; 12(11):947-51. PubMed ID: 8265287
    [No Abstract]   [Full Text] [Related]  

  • 35. Open trial of tacrine therapy in 70 HIV-infected patients.
    Fredj G; Dietlin F; Jasmin C; Maurisson G; Barbier M; Bayce P; Ratiney R; Rudant E; Debat P; Kalifa D
    Int J Clin Pharmacol Ther Toxicol; 1992 Sep; 30(9):313-6. PubMed ID: 1358832
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantitative p24 antigenaemia for monitoring response to antiretroviral therapy in HIV-1 group O-infected patients.
    Machuca A; Gutiérrez M; Mur A; Soriano V
    Antivir Ther; 1998; 3(3):187-9. PubMed ID: 10682137
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV-1 sensitivity to zidovudine and clinical outcome in children.
    Tudor-Williams G; St Clair MH; McKinney RE; Maha M; Walter E; Santacroce S; Mintz M; O'Donnell K; Rudoll T; Vavro CL
    Lancet; 1992 Jan; 339(8784):15-9. PubMed ID: 1345951
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The antiviral effect of zidovudine and ribavirin in clinical trials and the use of p24 antigen levels as a virologic marker.
    Spector SA; Kennedy C; McCutchan JA; Bozzette SA; Straube RG; Connor JD; Richman DD
    J Infect Dis; 1989 May; 159(5):822-8. PubMed ID: 2496173
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Foscarnet decreases human immunodeficiency virus RNA.
    Kaiser L; Perrin L; Hirschel B; Furrer H; Von Overbeck J; Olmari M; Yerly S
    J Infect Dis; 1995 Jul; 172(1):225-7. PubMed ID: 7797916
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship of virologic, immunologic, and clinical parameters in infants with vertically acquired human immunodeficiency virus type 1 infection.
    Muñoz-Fernández MA; Obregón E; Navarro J; Börner C; Gurbindo MD; Sampelayo TH; Fernández-Cruz E
    Pediatr Res; 1996 Oct; 40(4):597-602. PubMed ID: 8888289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.